Archives
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
HOBt in Amide Bond Formation: A Route-Design Lens
2026-09-28
HOBt (1-Hydroxybenzotriazole) is more than a peptide coupling additive: it can shape stereochemical control, active-ester chemistry, and medicinal-chemistry route design. This article examines its mechanistic value through the synthesis of indazole-based glucagon receptor antagonists.
-
ALC-0159 and the Missing Layer in mRNA Imaging
2026-09-28
ALC-0159 is a PEG-conjugated lipid excipient for mRNA lipid nanoparticles, not an imaging reporter. This article explains how to interpret PET measurements of encoded antigen expression without confusing particle distribution, protein production, and vaccine activity.
-
Olaparib (AZD2281) in DNA Damage Research
2026-09-27
Use Olaparib to connect PARP inhibition with measurable DNA-damage phenotypes—and, in carefully designed models, test how repair stress shapes tumor immune responsiveness. This workflow emphasizes BRCA1-versus-BRCA2 comparisons, controlled combination experiments, and practical checks for solvent, timing, and assay interpretation.
-
Patient-Derived Gastric Cancer Assembloids in Context
2026-09-26
This study developed patient-specific gastric cancer assembloids by combining tumor organoids with matched stromal cell subpopulations. The co-cultures retained epithelial and stromal features and showed gene-expression and drug-response differences from organoid monocultures, highlighting the importance of tumor context when interpreting preclinical screens.
-
Ruxolitinib Phosphate: Reliable JAK/STAT Assays
2026-09-25
A practical guide to using Ruxolitinib phosphate (SKU A3781) in cell viability, proliferation, and cytotoxicity workflows. It connects JAK1/2 potency and formulation data with assay design, interpretation, and evidence from an anaplastic thyroid cancer study.
-
Pronase E Workflows for TNBC Ferroptosis Research
2026-09-25
Use Pronase E as a controlled limited-proteolysis tool to probe protein accessibility and support target-engagement assays—not as a component of gramine’s reported anticancer mechanism. This practical workflow separates protease-treated samples from intact-protein and ferroptosis readouts, helping protect interpretation of the CUL3–MTDH axis.
-
Spatial Kidney Assembloids Improve Disease Modeling
2026-09-24
Huang et al. developed mouse and human kidney progenitor assembloids that organize nephron and collecting-system progenitors in a spatial arrangement resembling kidney development. The models show improved cellular complexity and maturation, and in vivo-grown PKD2-deficient human assembloids reproduce key features of polycystic kidney disease and its multicellular interactions.
-
Parathyroid hormone (1-34) (human) in CKD assays
2026-09-24
Use this defined PTH fragment to probe receptor signaling and test how endothelial responses may connect to CKD-associated valvular calcification. The workflow pairs rapid cAMP readouts with longer EndMT and endothelial–interstitial-cell experiments, while keeping proposed conditions distinct from published findings.
-
LINC01977 Super-Enhancer Hijacking in Early LUAD
2026-09-23
Zhang et al. describe a reciprocal circuit in which tumor-associated macrophage-associated TGF-β signaling activates the LINC01977 super-enhancer, while LINC01977 promotes SMAD3-dependent transcription and malignant behavior in lung adenocarcinoma. The findings connect enhancer regulation, immune context, and transcriptional coactivation, while suggesting experiments to test this pathway rather than establishing a treatment strategy.
-
Deoxycholic Acid Sodium Salt in Adipose Research
2026-09-23
Deoxycholic acid sodium salt is an amphiphilic bile-salt detergent with utility in membrane and protein workflows. The cited adipose study supports Netrin-1, PPARγ, and Wnt/β-catenin as biological benchmarks, but it does not establish sodium deoxycholate as a direct regulator of that pathway.
-
5-Methyl-CTP for Stable mRNA Workflows
2026-09-22
5-Methyl-CTP helps researchers engineer IVT-derived mRNA for greater stability and translation performance. This practical guide connects nucleotide substitution, quality control, and formulation-ready assay design with lessons from an H5N1 mRNA vaccine study in lactating dairy cows.
-
Iptacopan Monotherapy in PNH: Study Insights
2026-09-22
This phase 2 proof-of-concept study found that oral Iptacopan (LNP023) monotherapy rapidly reduced hemolysis and improved hemoglobin and transfusion outcomes in treatment-naive patients with paroxysmal nocturnal hemoglobinuria. Its main innovation was to test proximal alternative-pathway inhibition as a single-agent strategy rather than only as add-on treatment to terminal complement blockade.
-
METTL9–PRA1 Antifungal Defense in the Gut
2026-09-21
Bao et al. identify secreted METTL9 as a catalytic mucosal defense factor that methylates the Candida albicans zincophore PRA1, disrupting fungal zinc acquisition and limiting intestinal colonization. The study connects epithelial antifungal secretion with multidrug-resistant Candida auris and inflammatory bowel disease, while offering a mechanistically distinct framework for interpreting antifungal susceptibility and host–fungus interactions.
-
Fluconazole and the Next Era of Resistance Research
2026-09-21
Fluconazole is more than a benchmark antifungal compound. By pairing its defined action as a fungal cytochrome P450 enzyme 14α-demethylase inhibitor with PP2A–ATG pathway analysis, researchers can connect ergosterol disruption to biofilm adaptation, autophagy, and antifungal drug resistance research.
-
PPT and the ERα–FOXM1 Translational Axis
2026-09-20
PPT offers a selective pharmacological lever for separating ERα biology from ERβ activity and testing whether estrogen receptor signaling contributes causally to FOXM1-linked biology in female lung adenocarcinoma. This article connects receptor pharmacology, biomarker validation, experimental design, and translational decision-making without treating association as proof of mechanism.